Angelman Syndrome Market Forecast

DelveInsight’s ‘Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Angelman Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


The Angelman Syndrome market report provides analysis regarding current treatment practices, emerging drugs like Gaboxadol, potential therapies, market share of the individual therapies, historical, current and forecasted Angelman Syndrome market size from 2017 to 2030 segmented by seven major markets.


The report also covers current Angelman Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  •  EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  •  Japan

Study Period: 2017–2030

Angelman Syndrome- Disease Understanding and Treatment Algorithm


Angelman Syndrome Overview

Angelman syndrome (AS) is a complex genetic disorder that primarily affects the nervous system. The characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia). Most affected children also have recurrent seizures (epilepsy) and small head size (microcephaly).


It is caused by a variety of genetic abnormalities involving the chromosome 15q11-13 region, which is subjected to genomic imprinting. These include maternal deletion, paternal uniparental disomy, imprinting defects, point mutations or small deletions within the UBE3A gene, which lies within this region.


Delayed development becomes noticeable by the age of 6–12 months, and other common signs and symptoms usually appear in early childhood. Children with Angelman syndrome experience delays in reaching developmental milestones (developmental delays) and have severe learning disabilities. Besides, Angelman syndrome affects males and females in equal numbers.

Angelman Syndrome Treatment

This chapter covers the details of conventional and current medical therapies available in the Angelman Syndrome market for the treatment of the condition. It also provides the country-wise Angelman Syndrome treatment guidelines across the United States, Europe and Japan.


DelveInsight’s Angelman Syndrome market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Angelman Syndrome treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Angelman Syndrome Epidemiology

The Angelman Syndrome epidemiology chapters provide insights about historical and current Angelman Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Angelman Syndrome epidemiology is segmented by Prevalent and Diagnosed cases of Angelman Syndrome, Cases of Angelman Syndrome by Mutation Types and Angelman Syndrome cases by Clinical Manifestations.The report includes a thorough analysis of all segmentations.


In the US, the cases of Angelman Syndrome were found to be 21,715 in 2017. Moreover, the diagnosed cases of Angelman Syndrome were reported to be 19,543 in the United States. The United States accounts for the highest diagnosed cases of Angelman Syndrome.


According to DelveInsight’s, the total prevalent population of Angelman Syndrome in seven major markets was 57,716 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Among all the seven major markets, the United States accounts for the highest Prevalent Cases of Angelman Syndrome cases.

Angelman Syndrome Drug Chapters

Drug chapter segment of the Angelman Syndrome report encloses the detailed analysis of Angelman Syndrome pipeline drug. It also helps to understand the Angelman Syndrome clinical trial details, expressive pharmacological action, agreements of included drug and the latest news and press releases.


Treatment is focused entirely on the management of symptoms and supporting the health and well-being of the affected child or adult. The management of Angelman Syndrome revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. Ovid Therapeutics’ Gaboxadol is one of the therapies in the pipeline.

Angelman Syndrome Market Outlook

The Angelman Syndrome market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Angelman Syndrome market size with USD 110 million in 2017, while Spain had the smallest market size of Angelman Syndrome with USD 16 million in 2017.

Angelman Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Angelman Syndrome market or expected to get launched in the market during the study period 2017–2030. The analysis covers Angelman Syndrome market uptake by drugs; patient uptake by therapies; and sale of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of Angelman Syndrome market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.


Angelman Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Angelman Syndrome key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of Angelman Syndrome collaborations, acquisition and merger, licensing, patent details and other information for Angelman Syndrome emerging therapies.

Reimbursement Scenario in Angelman Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Angelman Syndrome domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Angelman Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights

  • In the coming years, Angelman Syndrome market scenario is expected to alter across the 7 MM due to launch of novel therapies with new mechanisms of action considering the high unmet medical need.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Angelman Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Angelman Syndrome Pipeline Analysis
  • Angelman Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Angelman Syndrome Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Angelman Syndrome Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Angelman Syndrome Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions


Market Insights:

  • What was the Angelman Syndrome market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Angelman Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Angelman Syndrome market size during the forecast period (2017–2030)?
  • At what CAGR, the Angelman Syndrome market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Angelman Syndrome market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Angelman Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Angelman Syndrome?
  • What is the historical Angelman Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Angelman Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Angelman Syndrome?
  • Out of all 7MM countries, which country would have the highest prevalent population of Angelman Syndrome during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Angelman Syndrome treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Angelman Syndrome in the USA, Europe, and Japan?
  • What are the Angelman Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Angelman Syndrome?
  • How many therapies are developed by each company for Angelman Syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Angelman Syndrome treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angelman Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Angelman Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Angelman Syndrome?
  • What are the global historical and forecasted market of Angelman Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Angelman Syndrome market
  • To understand the future market competition in the Angelman Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Angelman Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Angelman Syndrome market
  • To understand the future market competition in the Angelman Syndrome market


Which geography accounted for the largest Angelman Syndrome market size?

The United States accounted for the largest Angelman Syndrome market size.


What is forecasted Angelman Syndrome market size in 2030?

DelveInsight estimates an increase in Angelman Syndrome Market Size during the study period, 2017–2030


What are the present Angelman Syndrome market drivers?

Increasing Prevalence, Biomarkers related studies and Molecular-level Diagnosis aims at driving the market growth.


What are the Angelman Syndrome market barriers?

Lack of awareness and data, Emerging Trials and Economic Burden of the disease.


How many companies are developing drugs for Angelman Syndrome?

Currently, only four key pharma players are developing the drug for Angelman Syndrome.


Which are the leading companies in Angelman Syndrome market?

Key Players – Ovid Therapeutics, GeneTx Biotherapeutics and others.


How is epidemiology segmented for Angelman Syndrome?

Incident and Diagnosed Cases of Angelman Syndrome, Angelman Syndrome cases by Mutation Types and Angelman Syndrome cases by Clinical Manifestations.

1 Key Insights

2 Executive Summary of Angelman Syndrome

3 SWOT Analysis for Angelman Syndrome

4 Angelman Syndrome Market Overview at a Glance

4.1 Market Share (%) Distribution of Angelman Syndrome in 2017

4.2 Market Share (%) Distribution of Angelman Syndrome in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Cause

5.3 Signs and Symptoms

5.4 Related Disorders and Differential Diagnosis

5.5 Complications

5.6 Genetics of Angelman syndrome

5.7 Molecular Genetic Pathogenesis

5.8 Diagnosis

5.8.1 Clinical criteria for diagnosis

5.8.2 Disease History and Medical Conditions

5.9 Diagnostic Algorithm

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Angelman syndrome

7 Country Wise-Epidemiology of Angelman syndrome

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Cases of Angelman Syndrome in the United States

7.1.3 Diagnosed Prevalent Cases of Angelman Syndrome in the United States

7.1.4 Angelman Syndrome cases by Mutation Types in the United States

7.1.5 Angelman Syndrome associated with Clinical Manifestations in the United States

7.2 EU5

7.2.1 Assumptions and Rationale

7.3 Germany

7.3.1 Total Prevalent Cases of Angelman Syndrome in Germany

7.3.2 Diagnosed Prevalent Cases of Angelman Syndrome in Germany

7.3.3 Angelman Syndrome cases by Mutation Types in Germany

7.3.4 Angelman Syndrome associated with Clinical Manifestations in Germany

7.4 France

7.4.1 Total Prevalent Cases of Angelman Syndrome in France

7.4.2 Diagnosed Prevalent Cases of Angelman Syndrome in France

7.4.3 Angelman Syndrome cases by Mutation Types in France

7.4.4 Angelman Syndrome associated with Clinical Manifestations in France

7.5 Italy

7.5.1 Total Prevalent Cases of Angelman Syndrome in Italy

7.5.2 Diagnosed Prevalent Cases of Angelman Syndrome in Italy

7.5.3 Angelman Syndrome cases by Mutation Types in Italy

7.5.4 Angelman Syndrome associated with Clinical Manifestations in Italy

7.6 Spain

7.6.1 Total Prevalent Cases of Angelman Syndrome in Spain

7.6.2 Diagnosed Prevalent Cases of Angelman Syndrome in Spain

7.6.3 Angelman Syndrome cases by Mutation Types in Spain

7.6.4 Angelman Syndrome associated with Clinical Manifestations in Spain

7.7 The United Kingdom

7.7.1 Total Prevalent Cases of Angelman Syndrome in the United Kingdom

7.7.2 Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom

7.7.3 Angelman Syndrome cases by Mutation Types in the UK

7.7.4 Angelman Syndrome associated with Clinical Manifestations in the UK

7.8 Japan

7.8.1 Assumptions and Rationale

7.8.2 Total Prevalent Cases of Angelman Syndrome in Japan

7.8.3 Diagnosed Prevalent Cases of Angelman Syndrome in Japan

7.8.4 Angelman Syndrome cases by Mutation Types in Japan

7.8.5 Angelman Syndrome associated with Clinical Manifestations in Japan

8 Treatment and Management of Angelman syndrome

8.1 Recommendations for the management of Angelman Syndrome

8.2 Future treatment options for Angelman Syndrome

8.2.1 Gene Therapy

8.2.2 Topoisomerase Inhibitors

8.2.3 Minocycline

8.2.4 Cannabidiol (CBD)

8.2.5 Protein Phosphatase 2A (PP2A) Inhibitor

9 Unmet Needs

10 Organizations contributing toward Angelman Syndrome

11 KOL’s Views: Angelman Syndrome

12 Patient Journey

12.1 Journey toward a Diagnosis: Diagnosing a Rare form of Angelman Syndrome

13 Case Reports

13.1 A Case of Fundus Oculi Albinoticus Diagnosed as Angelman Syndrome by Genetic Testing – A Japanese Case Study

13.2 Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform: a case report of US

13.3 Angelman Syndrome: A Case Series Assessing Neurological Issues in Adulthood – A European Case Report

14 Emerging Therapies

14.1 Gaboxadol: Ovid Therapeutics

14.1.1 Product Description

14.1.2 Other Development Activities

14.1.3 Clinical Development

14.1.4 Safety and Efficacy

14.2 GeneTx Biotherapeutics

14.2.1 GTX-102

15 Future Gene Therapies

15.1 GeneTx Biotherapeutics

15.1.1 GTX-101

15.2 PTC Therapeutics: GT-AS/AGIL-AS:

15.2.1 Product Description

15.2.2 Other Development Activities

15.3 Sarepta Therapeutics and StrideBio

15.3.1 Development Activities

16 Angelman syndrome: Seven Major Market Analysis

16.1 Key Findings

16.2 Market Size of Angelman Syndrome in 7MM

17 Market Outlook by Country

17.1 The United States: Market Outlook

17.1.1 United States Market Size

17.2 EU-5 Countries: Market Outlook

17.2.1 Germany

17.2.2 France

17.2.3 Italy

17.2.4 Spain

17.2.5 United Kingdom

17.3 Japan: Market Outlook

17.3.1 Total Market Size of Angelman syndrome

17.3.2 Market Size of Angelman Syndrome by Therapies

18 Market Drivers

19 Market Barriers

20 Market Access and Reimbursement

21 Appendix

21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Table

Table 1: Summary of Angelman Syndrome Market, Epidemiology, and Key Events (2017–2030)

Table 2: Genetic mechanisms giving rise to Angelman syndrome

Table 3: Molecular genetic testing used in AS after DNA methylation analysis

Table 4: Prevalent Patient Population of Angelman Syndrome in 7MM (2017–2030)

Table 5: Total Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Table 6: Diagnosed Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Table 7: Angelman Syndrome cases by Mutation Types in the United States (2017–2030)

Table 8: Angelman Syndrome associated with Clinical Manifestations in the United States (2017–2030)

Table 9: Total Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Table 10: Diagnosed Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Table 11: Angelman Syndrome cases by Mutation Types in Germany (2017–2030)

Table 12: Angelman Syndrome associated with Clinical Manifestations in Germany (2017–2030)

Table 13: Total Prevalent Cases of Angelman Syndrome in France (2017–2030)

Table 14: Diagnosed Prevalent Cases of Angelman Syndrome in France (2017–2030)

Table 15: Angelman Syndrome cases by Mutation Types in France (2017–2030)

Table 16: Angelman Syndrome associated with Clinical Manifestations in France (2017–2030)

Table 17: Total Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Table 18: Diagnosed Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Table 19: Angelman Syndrome cases by Mutation Types in Italy (2017–2030)

Table 20: Angelman Syndrome associated with Clinical Manifestations in Italy (2017–2030)

Table 21: Total Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Table 22: Diagnosed Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Table 23: Angelman Syndrome cases by Mutation Types in Spain (2017–2030)

Table 24: Angelman Syndrome associated with Clinical Manifestations in Spain (2017–2030)

Table 25: Total Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Table 26: Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Table 27: Angelman Syndrome cases by Mutation Types in the UK (2017–2030)

Table 28: Angelman Syndrome associated with Clinical Manifestations in the UK (2017–2030)

Table 29: Total Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Table 30: Diagnosed Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Table 31: Angelman Syndrome cases by Mutation Types in Japan (2017–2030)

Table 32: Angelman Syndrome associated with Clinical Manifestations in Japan (2017–2030)

Table 33: Feeding & Diet Recommendations

Table 34: Development Recommendations

Table 35: Seizure Types—the following are typical of AS:

Table 36: Treatment for Seizures and CNS

Table 37: Recommendations for the management of Angelman Syndrome

Table 38: Recommendations for the management of Vision & Hearing

Table 39: Recommendations for the management of Behavior

Table 40: Recommendations for the management of Speech and Communication

Table 41: Recommendations for the management of Dental Issues and Drooling

Table 42: General health and Anesthesia Recommendations

Table 43: Scoliosis and Skeletal Recommendations

Table 44: Puberty and Sexual Health Recommendations

Table 45: Organizations contributing to Angelman syndrome

Table 46: Gaboxadol, Clinical Trial Description, 2020

Table 47: GTX-102, Clinical Trial Description, 2020

Table 48: Seven Major Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 49: United States Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 50: The US Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 51: Germany Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 52: Germany Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 53: France Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 54: France Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 55: Italy Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 56: Italy Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 57: Spain Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 58: Spain Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 59: United Kingdom Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 60: The UK Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Table 61: Japan Market Size of Angelman Syndrome in USD Million (2017–2030)

Table 62: Japan Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

List of Figure

Figure 1: SWOT Analysis

Figure 2: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 3: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 4: Imprinting map of Paternal and Maternal human Chromosome 15q11-13 around AS-1C

Figure 5: Diagnostic Algorithm

Figure 6: Prevalent Patient Population of Angelman Syndrome in 7MM (2017–2030)

Figure 7: Total Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Figure 8: Diagnosed Prevalent Cases of Angelman Syndrome in the United States (2017–2030)

Figure 9: Angelman Syndrome cases by Mutation Types in the United States (2017–2030)

Figure 10: Angelman Syndrome associated with Clinical Manifestations in the United States (2017–2030)

Figure 11: Total Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Figure 12: Diagnosed Prevalent Cases of Angelman Syndrome in Germany (2017–2030)

Figure 13: Angelman Syndrome cases by Mutation Types in Germany (2017–2030)

Figure 14: Angelman Syndrome associated with Clinical Manifestations in Germany (2017–2030)

Figure 15: Total Prevalent Cases of Angelman Syndrome in France (2017–2030)

Figure 16: Diagnosed Prevalent Cases of Angelman Syndrome in France (2017–2030)

Figure 17: Angelman Syndrome cases by Mutation Types in France (2017–2030)

Figure 18: Angelman Syndrome associated with Clinical Manifestations in France (2017–2030)

Figure 19: Total Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Figure 20: Diagnosed Prevalent Cases of Angelman Syndrome in Italy (2017–2030)

Figure 21: Angelman Syndrome cases by Mutation Types in Italy (2017–2030)

Figure 22: Angelman Syndrome associated with Clinical Manifestations in Italy (2017–2030)

Figure 23: Total Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Figure 24: Diagnosed Prevalent Cases of Angelman Syndrome in Spain (2017–2030)

Figure 25: Angelman Syndrome cases by Mutation Types in Spain (2017–2030)

Figure 26: Angelman Syndrome associated with Clinical Manifestations in Spain (2017–2030)

Figure 27: Total Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Figure 28: Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom (2017–2030)

Figure 29: Angelman Syndrome cases by Mutation Types in the UK (2017–2030)

Figure 30: Angelman Syndrome associated with Clinical Manifestations in the UK (2017–2030)

Figure 31: Total Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Figure 32: Diagnosed Prevalent Cases of Angelman Syndrome in Japan (2017–2030)

Figure 33: Angelman Syndrome cases by Mutation Types in Japan (2017–2030)

Figure 34: Angelman Syndrome associated with Clinical Manifestations in Japan (2017–2030)

Figure 35: Unmet Needs of Angelman syndrome

Figure 36: Seven Major Market Size of Angelman Syndrome in USD Million (2017–2030)

Figure 37: Market Size of Angelman Syndrome in the United States, USD Million (2017–2030)

Figure 38: The US Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 39: Market Size of Angelman Syndrome in Germany, USD Million (2017–2030)

Figure 40: Germany Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 41: Market Size of Angelman Syndrome in France USD Million (2017–2030)

Figure 42: France Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 43: Market Size of Angelman Syndrome in Italy, USD Million (2017–2030)

Figure 44: Italy Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 45: Market Size of Angelman Syndrome in Spain, USD Million (2017–2030)

Figure 46: Spain Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 47: Market Size of Angelman Syndrome in the United Kingdom, USD Million (2017–2030)

Figure 48: The UK Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 49: Market Size of Angelman Syndrome in Japan, USD Million (2017–2030)

Figure 50: Japan Market Size of Angelman Syndrome by Therapies in USD Million (2017–2030)

Figure 51: Market Drivers

Figure 52: Market Barriers

Angelman Syndrome market,

Angelman Syndrome market research,

Angelman Syndrome Companies,

Angelman Syndrome market trends,

Angelman Syndrome market forecast,

Angelman Syndrome market share,

Angelman Syndrome pipeline,

Angelman Syndrome treatment algorithm,

Angelman Syndrome drugs,

Angelman Syndrome sales forecasting,

Angelman Syndrome market size,

Angelman Syndrome disease,

Angelman Syndrome epidemiology,

Angelman Syndrome

  • Tags:
  • Angelman Syndrome market
  • Angelman Syndrome market research
  • Angelman Syndrome Companies
  • Angelman Syndrome market trends
  • Angelman Syndrome market forecast
  • Angelman Syndrome market share
  • Angelman Syndrome pipeline
  • Angelman Syndrome treatment algorit...
  • Angelman Syndrome drugs
  • Angelman Syndrome sales forecasting
  • Angelman Syndrome market size
  • Angelman Syndrome disease
  • Angelman Syndrome epidemiology
  • Angelman Syndrome

Forward to Friend

Need A Quote